Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 6/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 6/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 6/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 5/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.53 |
| ▸ | GBA1 | P04062 | 1/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.48 |
| ▸ | MAPT | P10636 | 5/20 | 0.48 |
| ▸ | LMNA | P02545 | 4/20 | 0.48 |
| ▸ | HTT | P42858 | 3/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.48 |
| ▸ | HPGD | P15428 | 2/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | CASP1 | P29466 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | ATM | Q13315 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL802439 | 0.83 | CYP1A2 (0.53) | CYP1A2CYP3A4CYP2C19CYP2D6ALDH1A1 | |
| SCHEMBL802096 | 0.77 | CYP1A2 (0.52) | CYP1A2CYP3A4CYP2C19CYP2D6ALDH1A1 | |
| SCHEMBL14164031 | 0.71 | KDM4E (0.50) | CYP1A2CYP3A4CYP2C19CYP2D6ALDH1A1 | |
| SCHEMBL3156932 | 0.66 | AURKA (0.51) | CYP1A2CYP3A4CYP2D6HTTMEN1 | |
| SCHEMBL1083779 | 0.64 | CYP1A2 (0.80) | CYP1A2CYP3A4CYP2C19CYP2D6ALDH1A1 | |
| SCHEMBL4216805 | 0.64 | LMNA (0.58) | ALDH1A1MAPK1KDM4EMAPTLMNA | |
| SCHEMBL14842053 | 0.64 | NOS2 (0.58) | ALDH1A1MAPK1KDM4EMAPTLMNA | |
| SCHEMBL16391961 | 0.63 | ABCG2 (0.54) | CYP1A2CYP3A4CYP2C19CYP2D6ALDH1A1 | |
| SCHEMBL11916176 | 0.61 | SMN1; SMN2 (0.63) | ALDH1A1MAPK1KDM4EMAPTLMNA | |
| SCHEMBL21796417 | 0.61 | KDM4E (0.68) | ALDH1A1GBA1KDM4EMAPTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160158230-A1 | 2,4- OR 4,6-DIAMINOPYRIMIDINE COMPOUNDS AS IDH2 MUTANTS INHIBITORS FOR THE TREATMENT OF CANCER | SERVIER PHARMACEUTICALS LLC | 2016-06-09 | — | — | US | claimed |
| EP-3019480-A1 | 2,4- OR 4,6-DIAMINOPYRIMIDINE COMPOUNDS AS IDH2 MUTANTS INHIBITORS FOR THE TREATMENT OF CANCER | Agios Pharmaceuticals, Inc. (US) | 2016-05-18 | — | — | EP | claimed |
| WO-2015006591-A1 | 2,4- OR 4,6-DIAMINOPYRIMIDINE COMPOUNDS AS IDH2 MUTANTS INHIBITORS FOR THE TREATMENT OF CANCER | AGIOS PHARMACEUTICALS, INC. (US) | 2015-01-15 | — | — | WO | claimed |
| US-10376510-B2 | 2,4- or 4,6-diaminopyrimidine compounds as IDH2 mutants inhibitors for the treatment of cancer | AGIOS PHARMACEUTICALS, INC. (US) | 2019-08-13 | — | — | US | disclosed |
| US-20160158230-A1 | 2,4- OR 4,6-DIAMINOPYRIMIDINE COMPOUNDS AS IDH2 MUTANTS INHIBITORS FOR THE TREATMENT OF CANCER | SERVIER PHARMACEUTICALS LLC | 2016-06-09 | — | — | US | disclosed |
| EP-3019480-A1 | 2,4- OR 4,6-DIAMINOPYRIMIDINE COMPOUNDS AS IDH2 MUTANTS INHIBITORS FOR THE TREATMENT OF CANCER | Agios Pharmaceuticals, Inc. (US) | 2016-05-18 | — | — | EP | disclosed |
| WO-2015006591-A1 | 2,4- OR 4,6-DIAMINOPYRIMIDINE COMPOUNDS AS IDH2 MUTANTS INHIBITORS FOR THE TREATMENT OF CANCER | AGIOS PHARMACEUTICALS, INC. (US) | 2015-01-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160158230-A1 | 2,4- OR 4,6-DIAMINOPYRIMIDINE COMPOUNDS AS IDH2 MUTANTS INHIBITORS FOR THE TREATMENT OF CANCER | IDH2, IDH3B, IDH3A | CYP1A2 197/4885CYP3A4 939/4885CYP2C19 952/4885 |
| US-10376510-B2 | 2,4- or 4,6-diaminopyrimidine compounds as IDH2 mutants inhibitors for the treatment of cancer | IDH2, IDH3B, IDH3A | CYP1A2 197/4885CYP3A4 939/4885CYP2C19 952/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.